Fate Therapeutics Inc. (NASDAQ:FATE) shares traded up 4.5% during mid-day trading on Friday . The stock traded as high as $2.12 and last traded at $2.07, with a volume of 527,613 shares traded. The stock had previously closed at $1.98.

Several research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. HC Wainwright assumed coverage on shares of Fate Therapeutics in a research report on Thursday. They set a “buy” rating and a $9.00 price target on the stock. BMO Capital Markets reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, May 10th. Leerink Swann reiterated an “outperform” rating and set a $4.00 price target on shares of Fate Therapeutics in a research report on Tuesday, June 21st. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $6.17.

The firm’s market cap is $59.75 million. The stock’s 50-day moving average price is $1.78 and its 200-day moving average price is $1.86.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.04. Analysts anticipate that Fate Therapeutics Inc. will post ($1.23) earnings per share for the current year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.